Verve Therapeutics

Verve Therapeutics is a biotechnology startup that is committed to combating cardiovascular disease with the slogan "We are on a mission to protect the world from cardiovascular disease." Founded in 2018 and based in Boston, Massachusetts, the company is at the forefront of developing transformative, once-and-done gene editing therapies for coronary heart disease. Led by world-leading experts in cardiovascular medicine, human genetics, and gene editing, Verve Therapeutics is focused on creating precision genetic medicines with its flagship product, VERVE-101, designed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. The company's gene editing medicines aim to safely and permanently lower LDL cholesterol and triglyceride levels by mimicking naturally occurring gene variants in adults. In November 2023, Verve Therapeutics secured a significant $143.80M Post-IPO Equity investment, consolidating its position as a pioneering player in the biotechnology industry. Additionally, the company was distinguished as one of the "Best Places to Work" by the Boston Globe in 2023, reflecting its positive company culture and working environment. Overall, Verve Therapeutics is demonstrating strong potential in advancing genetic medicines and attracting notable investor interest, positioning itself as a key player in the fight against cardiovascular disease.